The Cannabinoid Receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic intervention
- 24 March 2012
- journal article
- Published by Elsevier BV in Pharmacological Research
- Vol. 66 (1), 88-94
- https://doi.org/10.1016/j.phrs.2012.03.011
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpuraHaematologica, 2011
- Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 ReceptorsPLOS ONE, 2010
- Cannabinoid Receptor Type 1- and 2-mediated Increase in Cyclic AMP Inhibits T Cell Receptor-triggered SignalingPublished by Elsevier BV ,2009
- A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortiumNature Genetics, 2009
- Replication of celiac disease UK genome-wide association study results in a US populationHuman Molecular Genetics, 2009
- The Cannabinoid Receptor 2 Is Critical for the Host Response to SepsisPublished by The American Association of Immunologists ,2009
- Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppressionImmunobiology, 2009
- Emerging role of the cannabinoid receptor CB2in immune regulation: therapeutic prospects for neuroinflammationExpert Reviews in Molecular Medicine, 2009
- Newly identified genetic risk variants for celiac disease related to the immune responseNature Genetics, 2008
- A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21Nature Genetics, 2007